Cryoport Q3 revenue $56.7M (+407% YoY); net loss $0.18/share; 582 clinical trials supported

Cryoport, Inc.

2021-Q3 EPS reported -$0.46 revenue$166,168,000

Total revenue $56.7M for Q3 2021, up 407% YoY; organic growth 38%.
Net loss attributable to common stockholders $8.5M ($0.18 per share), vs $11.4M ($0.29) in Q3 2020.
Adjusted EBITDA $5.6M in Q3 2021, vs -$0.7M in Q3 2020; gross margin 41.5% vs 54.2%.
Supported 582 clinical trials (up from 561 in Q2 2021) and eight commercial therapies in regenerative medicine.
Cash and short-term investments $349.5M as of Sep 30, 2021, up from $93.3M on Dec 31, 2020.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.